


PHARMACEUTICAL 2020



SELLAS Life Sciences Group Inc. Rank 305 of 362





PHARMACEUTICAL 2020



SELLAS Life Sciences Group Inc. Rank 305 of 362

The relative strengths and weaknesses of SELLAS Life Sciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELLAS Life Sciences Group Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 130% points. The greatest weakness of SELLAS Life Sciences Group Inc. is the variable Net Income, reducing the Economic Capital Ratio by 250% points.

The company's Economic Capital Ratio, given in the ranking table, is -528%, being 225% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	8,242
Cost of Goods Sold	0
Intangible Assets	1,914
Liabilities, Current	5,290
Liabilities, Non-Current	0
Other Assets	6,453
Other Compr. Net Income	0
Other Expenses	2,752
Other Liabilities	5,226
Other Net Income	668
Property and Equipment	0
Research and Development	7,285
Revenues	0
Selling, General and Administrative Expense	9,923

Output Variable	Value in 1000 USD
Assets	16,609
Liabilities	10,516
Expenses	19,960
Stockholders Equity	6,093
Net Income	-19,292
Comprehensive Net Income	-19,292
Economic Capital Ratio	-528%